期刊文献+

前列腺癌中基质金属蛋白酶7,9的表达及其与VEGF的关系 被引量:8

下载PDF
导出
摘要 目的探讨基质金属蛋白酶7,9在前列腺癌转移侵袭中的作用,以及VEGF与基质金属蛋白酶的关系。方法采用免疫组织化学和形态定量分析方法分析MMP7及MMP9表达情况,同时培养PC3M细胞并采用Boyden小室侵袭试验及酶谱分析观察MMP9及其与VEGF在前列腺癌中的作用。结果前列腺癌各分级中MMP7和MMP9的表达均有显著性差异(P<0.001)。Boyden小室侵袭实验显示,不同试验组穿透Matrigel的细胞数依次递减,即PC3M>PC3M+MMP9Ab(1∶100)>PC3M+MMP9Ab(1∶50),均有显坐的统计学差异(P<0.01)。酶谱分析观察发现,直接培养于培养皿表面的PC3M细胞仅有稳定的MMP-9和MMP-2酶原表达,但PC3M细胞与VEGF共孵育组条件培养基中MMP-9酶原含量以VEGF剂量依赖的方式增加。结论MMP7和MMP9可作为肿瘤侵袭和转移的判定指标。VEGF与MMPs的分泌有关,其机制有待于进一步探讨。
出处 《中国老年学杂志》 CAS CSCD 北大核心 2007年第14期1385-1387,共3页 Chinese Journal of Gerontology
基金 吉林省科技发展计划(200505182) 吉林大学青年教师基金(2003QN043)
  • 相关文献

参考文献2

二级参考文献15

  • 1Bigler SA,Deer RE, Brawer MK,et al. Comparision of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol, 1993,24: 220.
  • 2Gleave M, Hsieh JT,Gao CA, et al. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone libroblasts. Cancer Res, 1991,51:375-376.
  • 3Xue Y, Li J, Latijnhouwers MA, et al. Expression of periglandular tenascin-C and basement membrane laminin in normal prostate,benign prostatic hyperplasia and prostate carcinoma. Br J Urol,1998,81:844-851.
  • 4Rabinovitz I,Cress AE,Nalge RB, et al. Biosynthesis and secretion of laminin and s-laminin by human prostate carcionma cell line. Prostate, 1994,25 : 97-107.
  • 5Pfohler C, Fixemer T,Jung V, et al. In situ hybridizaton analysis of genes coding collagen IV alpha 1 chain and s-laminin in prostate tissue and prostate cancer: increased basement membrane gene expession in high-grade and metastatic lesions. Prostate,1998,36 : 143-150.
  • 6Hao J ,Jackson L,Calaluce R,et al. Investigation into the mechanism of the loss of laminin-S(alpha 3 beta 3 gamma 2) expression in prostate cancer. Am J Pathol,2001,158:1129-1135.
  • 7Begem G, Brekken R, McMahon G, et al. Marx metalloproteinase-9 triggers the angiogenic switch during carcinogenesis[J].Nature Cell Biology,2000,2(10):737—744.
  • 8Shimizu M,Saitoh Y,hoh H.Immunohistochemical staining of Ha-ras oncogene product in normal,benign and malignant human pancreatic tissues[J].Hum Pathol,1990,21(6):607—612.
  • 9Kugler A.Matrix metalloproteinases and their inhibitors[J].Anticancer Res,1999.19(2c):1589—1592.
  • 10Nelson AR,Fingleton B,Rothenberg ML,et al.Matrix metalloproteinases:biologic activity and clinical implications [J].Journal of Clinical Oncology,2000,18(5):1135—1149.

共引文献14

同被引文献88

  • 1孙颖浩,高旭.前列腺癌内分泌治疗的合理选择[J].现代泌尿外科杂志,2007,12(1):1-3. 被引量:7
  • 2Hannon GJ. RNA interference . Nature,2002,418 (6894) : 244 - 251.
  • 3Ni Y , Sun S , Oparaoeha I , et al . Generation of a packaging cell line for prolonged large - scale production of high - titer HIV - 1 - based lentiviral vector. J Gene Med , 2005 , 7 (6) : 818.
  • 4Schumacker PT. Hypoxia - inducible factor - 1 ( HIF - 1 ). Crit Care Med , 2005 , 33:423 -425.
  • 5Shannon AM , Bouchier - Hayes DJ, Condron CM , et al . Tumour hypoxia, chemotherapeutic resistance and hypoxia - related therapies. Cancer Treat Rev , 2003 , 29 (4) : 297-307.
  • 6Zhong H , De Marzo AM , Laughner E , et al . Overexpression of hypoxia- inducible factor lalpha in common human cancers and their metastases. Cancer Res , 1999 , 1559:5830-5835.
  • 7Pugh CW , Rateliffe PJ. Regulation of angiogenesis by hypoxia : role of the HIF system. Nat Med , 2003 , 9 : 677 - 684.
  • 8Yeo EJ , Ryu JH , Chun YS , et al . YC - 1 induces S cell cycle arrest and apoptosis by activating checkpoint kinases. Cancer Res , 2006 , 66 (12) : 6345 - 6352.
  • 9Mabjeesh NJ, Amir S. Hypoxia - inducible factor(HIF) in human tumorigenesis. Histol Histopathol , 2007, 22 (5) : 559 -572.
  • 10Brown LM , Cowen RL , Debray C , et al . Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor - 1. Mol Pharmacol , 2006 , 69 (2) : 411 -418.

引证文献8

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部